select a format

Single User License
USD 250 INR 16073
Site License
USD 500 INR 32145
Corporate User License
USD 750 INR 48218

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ... "Mohit Mittal, Consultant, KPMG Advisory Services"

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies.... "Mustafa Masood, Financial Analyst , Coldwell Banker Riyadh"

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"


PDL BioPharma Inc (PDLI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile

PDL BioPharma Inc (PDLI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile


  • Products Id :- GDPH32141D
  • |
  • Pages: 39
  • |
  • July 2017
  • |
  • |
  Request for Sample Report

Executive Summary

Summary

PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions and non-dilutive growth capital to late-stage public and private healthcare companies. PDL provides companies, academic institutions, and inventors with an immediate financial monetization of royalty streams for acquiring new income generating assets. The company also carries out the humanization of monoclonal antibodies for facilitating the discovery of targeted treatments for cancer and other immunologic diseases. PDL is headquartered in Incline Village, Nevada, the US.

PDL BioPharma Inc (PDLI)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

Business Description-A brief description of the company's operations.

Key Employees-A list of the key executives of the company.

Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

Key Competitors-A list of the key competitors of the company.

Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications
ankur [@] kenresearch.com
+91-9015378249
www.kenresearch.com

Table of Contents

Table of Contents 2

List of Tables 3

List of Figures 4

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 11

Asset Purchase 11

Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11

PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 11

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 13

PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 14

PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 16

Equity Offering 17

Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 17

Debt Offering 18

PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 18

PDL BioPharma Completes Public Offering Of Notes Due 2018 For USD300 Million 19

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD25 Million 21

PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For USD155 Million 21

PDL BioPharma Inc-Key Competitors 23

Key Employees 24

Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Recent Developments 26

Financial Announcements 26

May 03, 2017: PDL BioPharma Announces First Quarter 2017 Financial Results 26

Mar 01, 2017: PDL BioPharma Announces Fourth Quarter and Year End 2016 Financial Results 28

Nov 03, 2016: PDL BioPharma Announces Third Quarter 2016 Financial Results 30

Aug 04, 2016: PDL BioPharma Announces Second Quarter 2016 Financial Results 32

May 04, 2016: PDL BioPharma Announces First Quarter 2016 Financial Results 35

Feb 22, 2016: PDL BioPharma Announces Fourth Quarter and Full Year 2015 Financial Results 36

Legal and Regulatory 38

Dec 19, 2016: Lensar Strategic Restructure In Partnership With Pdl Biopharma

Appendix 39

Methodology 39

About GlobalData 39

Contact Us 39

Disclaimer 39

List of Figures

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 1

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 1

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 1

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 1

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8

PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9

List of Tables

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 1

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5

PDL BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7

PDL BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8

PDL BioPharma Inc, Medical Devices Deals, 2011 to YTD 2017 9

PDL BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10

Noden Pharma Acquires Rights to Tekturna and Tekturna HCT from Novartis 11

PDL BioPharma Acquires Portion of Zalviso Royalty Rights from AcelRx Pharma for USD65 Million 11

PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 13

PDL BioPharma Acquires 75% of Royalty Interest in Cerdelga from University of Michigan for USD65.6 Million 14

PDL BioPharma Acquires Portfolio of Diabetes Royalty Rights and Milestones from Depomed for USD240.5 Million 16

Noden Pharma Raises USD75 Million in First Tranche of Private Placement of Shares 17

PDL BioPharma Completes Public Offering of 2.75% Convertible Senior Notes due 2021 for USD150 Million 18

PDL BioPharma Completes Public Offering Of Notes Due 2018 For USD300 Million 19

Durata Therapeutics Completes First Tranche Of Private Placement Of Debt Securities For USD25 Million 21

PDL BioPharma Completes Public Offering Of Convertible Senior Notes Due 2015 For USD155 Million 21

PDL BioPharma Inc, Key Competitors 23

PDL BioPharma Inc, Key Employees 24

PDL BioPharma Inc, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

PDL BioPharma Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.


Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com